Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile.

Farías MM

Archives of endocrinology and metabolism17 Sept 2024Cited by 1 (Europe PMC)

PMID39420938PMCIDPMC11460972DOI10.20945/2359-4292-2023-0234PepBankPUB-39420938

Summary

ObjectiveBariatric surgery has several benefits, including sustainable weight loss and improvement or resolution of metabolic comorbidities. However, despite initially successful weight loss, weight regain occurs during long-term follow-up, and many patients are unable to reach or maintain their target weight goals. Liraglutide is a therapy for obesity aimed at preventing weight regain.Materials and methodsThis retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.ResultsTreatment with liraglutide at a median dose of 1.2 mg was associated with a mean weight loss from baseline to 3, 6, 12, 24, and 36 months of 5%, 7.7%, 7.6%, 5.8%, and 5.1%, respectively. The mean body mass index reduction was 14.8% at 36 months. Dropout rates were consistent with those of usual obesity treatments. Overall, 70% of the patients were receiving other weight-loss drugs. Liraglutide was well tolerated, but cost barriers led to several patients interrupting its use.ConclusionLiraglutide is an effective and safe treatment for weight reduction after bariatric surgery in patients receiving routine clinical care in Chile.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studySafety outcome
In patients after bariatric surgery, dropout rates with liraglutide were consistent with those of usual obesity treatments.
In plain wordsAfter bariatric surgery, dropout rates with liraglutide were in line with those of usual obesity treatments.
Peptide
Liraglutide
Outcome
No significant changeDropout rate
Study
n: not reported in source
Comparator
Usual obesity treatments
Outcome group
Adverse events · Whole body
Studied dose
median 1.2 mg · 36 months follow-upAs given in this study (human).
Source sentences
Summary
Dropout rates were consistent with those of usual obesity treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.
Show in the study text Report a problemFND-3942093803
02HumanObservational studySafety outcome
In patients after bariatric surgery, liraglutide was reported as well tolerated.
In plain wordsAfter bariatric surgery, liraglutide was reported as well tolerated.
Peptide
Liraglutide
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
median 1.2 mg · 36 months follow-upAs given in this study (human).
Source sentences
Summary
Liraglutide was well tolerated
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.
Show in the study text Report a problemFND-3942093804
03HumanObservational studyOther
In patients after bariatric surgery, cost barriers led several patients to interrupt liraglutide.
In plain wordsAfter bariatric surgery, cost barriers made several patients stop liraglutide.
Peptide
Liraglutide
Outcome
Not applicableTreatment interruption because of cost
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
median 1.2 mg · 36 months follow-upAs given in this study (human).
Source sentences
Summary
cost barriers led to several patients interrupting its use.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.
Show in the study text Report a problemFND-3942093805

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients after bariatric surgery, a liraglutide regimen at a median dose of 1.2 mg, with 70% of patients also receiving other weight-loss drugs, was associated with mean weight loss of 5% at 3 months, 7.7% at 6 months, 7.6% at 12 months, 5.8% at 24 months and 5.1% at 36 months.
In plain wordsAfter bariatric surgery, people taking liraglutide, 70% also on other weight-loss drugs, lost 5% to 7.7% of weight on average, 5.1% at 36 months.
Peptide
Liraglutide
Outcome
DecreaseMean weight loss from baseline at 3 to 36 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
5%
3 months
Weight loss
7.7%
6 months
Weight loss
7.6%
12 months
Weight loss
5.8%
24 months
Weight loss
5.1%
36 months
Source sentences
Summary
Treatment with liraglutide at a median dose of 1.2 mg was associated with a mean weight loss from baseline to 3, 6, 12, 24, and 36 months of 5%, 7.7%, 7.6%, 5.8%, and 5.1%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.
Summary · context
Overall, 70% of the patients were receiving other weight-loss drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3942093801
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients after bariatric surgery, of whom 70% also received other weight-loss drugs, the mean body mass index reduction with a liraglutide regimen was 14.8% at 36 months.
In plain wordsAfter bariatric surgery, people taking liraglutide, 70% also on other weight-loss drugs, had a mean body mass index reduction of 14.8% at 36 months.
Peptide
Liraglutide
Outcome
DecreaseBody mass index reduction at 36 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
BMI reduction
14.8%
36 months
Source sentences
Summary
The mean body mass index reduction was 14.8% at 36 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.
Summary · context
Overall, 70% of the patients were receiving other weight-loss drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3942093802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.